留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

恶性胶质瘤化疗的过去、现在和未来

张熠丹 马文斌 王任直

张熠丹, 马文斌, 王任直. 恶性胶质瘤化疗的过去、现在和未来[J]. 协和医学杂志, 2012, 3(3): 344-349. doi: 10.3969/j.issn.1674-9081.2012.03.020
引用本文: 张熠丹, 马文斌, 王任直. 恶性胶质瘤化疗的过去、现在和未来[J]. 协和医学杂志, 2012, 3(3): 344-349. doi: 10.3969/j.issn.1674-9081.2012.03.020

恶性胶质瘤化疗的过去、现在和未来

doi: 10.3969/j.issn.1674-9081.2012.03.020
详细信息
    通讯作者:

    马文斌 电话: 010-69156071, E-mail: mawb2001@hotmail.com

  • 中图分类号: R739.41

  • 表  1  恶性胶质瘤靶向化疗药物作用目标分类、作用靶点及临床试验

    作用目标分类 英文名称 中文名称 作用靶点 临床试验
    Ras通路 Tipifarnib 替吡法尼 法呢酰基转移酶抑制剂 Ⅱ期
    Raf/MEK通路 Sorafenib 索拉非尼 Raf抑制剂 Ⅱ期
    CI1040 MEK抑制剂 Ⅱ期
    PI3K/Akt通路 Wortmannin 渥曼青霉素 PI3K抑制剂
    LY294002 PI3K抑制剂
    Staurosporine 星形孢菌素 PI3K抑制剂
    mTOR通路 Sirolimus 西罗莫司 mTOR抑制剂 Ⅱ期
    Everolimus 依维莫司 mTOR抑制剂 Ⅱ期
    Ridaforolimus mTOR抑制剂
    VEGF/VEGFR Bevacizumab 贝伐单抗 VEGF抑制剂 Ⅳ期
    IMC1C11 VEGFR-2抑制剂
    DC101 VEGFR-2抑制剂
    Vatalanib 瓦他拉尼 间接VEGFR抑制剂(酪氨酸激酶抑制剂) Ⅱ期
    Cediranib 西地尼布 间接VEGFR抑制剂(酪氨酸激酶抑制剂) Ⅱ期
    Pazopanib 帕唑帕尼 VEGFR-2抑制剂
    Sunitinib 舒尼替尼 VEGFR-2抑制剂 Ⅱ期
    Vandetanib 凡德他尼 VEGFR-2抑制剂 Ⅱ期
    XL184 VEGFR-2抑制剂
    EGF/EGFR Cetuximab 西妥昔单抗 EGFR抑制剂 Ⅱ期
    mAb 806 EGFR抑制剂
    Gefitinib 吉非替尼 EGFR抑制剂 Ⅱ期
    Erlotinib 埃罗替尼 EGFR抑制剂 Ⅱ期
    Lapatinib 拉帕替尼 EGFR抑制剂 Ⅱ期
    Nimotuzumab 尼妥珠单抗 EGFR抑制剂
    PDGF/PDGFR Imatinib 伊马替尼 间接PDGFR抑制剂(酪氨酸激酶抑制剂) Ⅱ期
    Tandutinib 坦度替尼 PDGFR抑制剂 Ⅱ期
    Dasatinib 达沙替尼 PDGFR抑制剂 Ⅱ期
    EGF:表皮生长因子; EGFR:表皮生长因子受体; VEGF:血管内皮生长因子; VEGFR:血管内皮生长因子受体; PDGF:血小板源性生长因子; PDGFR:血小板源性生长因子受体
    下载: 导出CSV
  • [1] Davis FG, McCarthy BJ. Current epidemiological trends and surveillance issues in brain tumors[J]. Expert Rev Anticancer Ther, 2001, 1:395-401. doi:  10.1586/14737140.1.3.395
    [2] Avgeropoulos NG, Batchelor TT. New treatment strategies for malignant gliomas[J]. Oncologist, 1999, 4:209-224. doi:  10.1634/theoncologist.4-3-209
    [3] Ushio Y, Hayakawa T, Hasegawa H, et al. Chemotherapy of malignant gliomas[J]. Neurosurg Rev, 1984, 7:3-12. doi:  10.1007/BF01743285
    [4] Macdonald DR, Cascino TL, Schold SC, et al. Response criteria for phase Ⅱ studies of supratentorial malignant glio-ma[J]. J Clin Oncol, 1990, 8:1277-1280. doi:  10.1200/JCO.1990.8.7.1277
    [5] Levin VA, Crafts DC, Norman DM, et al. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors[J]. J Neurosurg, 1977, 47:329-335. doi:  10.3171/jns.1977.47.3.0329
    [6] Kornblith PL, Walker M. Chemotherapy for malignant gliomas[J]. J Neurosurg, 1988, 68:1-17. doi:  10.3171/jns.1988.68.1.0001
    [7] Anderson B, Anderson B Jr. Necrotizing uveitis incident to perfusion of intractraial malignancies with nitrogen mustard or related compounds[J]. Trans Am Ophthalmol Soc, 1960, 58:95-104. http://europepmc.org/abstract/MED/13683174
    [8] Galanis E, Buckner JC, Burch PA, et al. Phase Ⅱ trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma:North Central Cancer Treatment Group results[J]. J Clin Oncol, 1998, 16:2953-2958. doi:  10.1200/JCO.1998.16.9.2953
    [9] Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial[J]. J Neurosurg, 1978, 49:333-343. doi:  10.3171/jns.1978.49.3.0333
    [10] Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study[J]. Cancer, 1983, 52:997-1007. doi:  10.1002/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO;2-2
    [11] Kaye AH, Laidlaw JD. Chemotherapy of gliomas[J]. Curr Opin Neurol Neurosurg, 1992, 5:526-533. http://europepmc.org/abstract/MED/1515691
    [12] Lassman LP, Pearce GW, Gang J. Sensitivity of intracranial gliomas to vincristine sulphate[J]. Lancet, 1965, 1:296-298. http://europepmc.org/abstract/MED/14247875
    [13] Kaneko S, Abe H, Aida T, et al. Evaluation of radiation immunochemotherapy in the treatment of malignant glioma. Combined use of ACNU, VCR and PS-K[J]. Hokkaido Igaku Zasshi, 1983, 58:622-630. http://www.ncbi.nlm.nih.gov/pubmed/6584394/
    [14] Hildebrand JG. Chemotherapy of malignant glioma. Results of studies of the EORTC group of brain tumors[J]. Rev Neurol (Paris), 1992, 148:435-440. http://www.ncbi.nlm.nih.gov/pubmed/1448663
    [15] Jeremic B, Jovanovic D, Djuric LJ, et al. Advantage of postradiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas[J]. J Chemother, 1992, 4:123-126. doi:  10.1080/1120009X.1992.11739152
    [16] Ushio Y, Abe H, Suzuki J, Tanaka R, et al. Evaluation of ACNU alone and combined with tegafur as additions to radiotherapy of the treatment of malignant gliomas-a cooperative clinical trial[J]. No To Shinkei, 1985, 37:999-1006. http://www.ncbi.nlm.nih.gov/pubmed/3000412
    [17] Kitahara M, Katakura R, Mori T, et al. Combined effect of ACNU and 5-fluorouracil on spheroids of rat glioma cells[J]. Neurol Med Chir (Tokyo), 1984, 24:747-757. doi:  10.2176/nmc.24.747
    [18] Shapiro WR, Green SB, Burger PC, et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma[J]. J Neurosurg, 1992, 76:772-781. doi:  10.3171/jns.1992.76.5.0772
    [19] Menei P, Boisdron-Celle M, Croue A, et al. Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats[J]. Neurosurgery, 1996, 39:117-123; discussion 23-24. doi:  10.1097/00006123-199607000-00023
    [20] Stewart DJ, Richard MT, Benoit B, et al. Cisplatin plus cytosine arabinoside in adults with malignant gliomas[J]. J Neurooncol, 1984, 2:29-34. doi:  10.1007/BF00165155
    [21] Luyendijk W, van Beusekom GT. Chemotherapy of cerebral gliomas with intra-carotid methotrexate-infusion[J]. Acta Neurochir (Wien), 1966, 15:234-248. doi:  10.1007/BF01406785
    [22] Dhanikula RS, Argaw A, Bouchard JF, et al. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas:enhanced efficacy and intratumoral transport capability[J]. Mol Pharm, 2008, 5:105-116. doi:  10.1021/mp700086j
    [23] Hayakawa T, Ushio Y, Mogami H, et al. The uptake, distribution and anti-tumor activity of bleomycin in gliomas in the mouse[J]. Eur J Cancer, 1974, 10:137-142. doi:  10.1016/0014-2964(74)90145-5
    [24] Zhao KM, Chen JM, Zuo HZ, et al. Modulation of O6-methylguanine-DNA methyltransferase-mediated nimustine resistance in recurrent malignant gliomas by streptozotocin-a preliminary report[J]. Anticancer Res, 1995, 15:645-648. http://www.ncbi.nlm.nih.gov/pubmed/7763050
    [25] Yoshida D. Clinical research of the treatment of malignant gliomas by local administration of adriamycin. A statistical study of 118 cases[J]. Nippon Ika Daigaku Zasshi, 1988, 55:544-554. doi:  10.1272/jnms1923.55.544
    [26] Pouillart P, Mathe G, Thy TH, et al. Treatment of malignant gliomas and brain metastases in adults with a combination of adriamycin, VM 26, and CCNU. Results of a phase Ⅱ trail[J]. Cancer, 1976, 38:1909-1916. doi:  10.1002/1097-0142(197611)38:5<1909::AID-CNCR2820380507>3.0.CO;2-Q
    [27] Glioma meta-Analysis Frialists (GMT) Group. Chemotherapy for high-grade glioma[J]. Cochrane Database Syst Rev, 2002:CD003913.
    [28] Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system[J]. Acta Neuropathol, 2007, 114:97-109. doi:  10.1007/s00401-007-0243-4
    [29] Stevens MF, Hickman JA, Stone R, et al. Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl) imidazo[5, 1-d]-1, 2, 3, 5-tetrazin-4(3H) -one, a novel broad-spectrum antitumor agent[J]. J Med Chem, 1984, 27:196-201. doi:  10.1021/jm00368a016
    [30] O'Reilly SM, Newlands ES, Glaser MG, et al. Temozolomide:a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours[J]. Eur J Cancer, 1993, 29A:940-942. http://europepmc.org/abstract/MED/8499146
    [31] Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med, 2005, 352:987-996. doi:  10.1056/NEJMoa043330
    [32] Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma[J]. N Engl J Med, 2005, 352:997-1003. doi:  10.1056/NEJMoa043331
    [33] Fukushima T, Takeshima H, Kataoka H. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT[J]. Anticancer Res, 2009, 29:4845-4854. http://new.med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_JJ0217511326
    [34] Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme[J]. J Clin Oncol, 2007, 25:4722-4729. doi:  10.1200/JCO.2007.12.2440
    [35] Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase Ⅱ trial of bevacizumab and irinotecan in recurrent malignant glioma[J]. Clin Cancer Res, 2007, 13:1253-1259. doi:  10.1158/1078-0432.CCR-06-2309
    [36] Tong RT, Boucher Y, Kozin SV, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors[J]. Cancer Res, 2004, 64:3731-3736. doi:  10.1158/0008-5472.CAN-04-0074
    [37] Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor[J]. Cancer Res, 2006, 66:7843-7848. doi:  10.1158/0008-5472.CAN-06-1010
    [38] Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma[J]. J Clin Oncol, 1999, 17:1516-1525. doi:  10.1200/JCO.1999.17.5.1516
    [39] Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan[J]. J Neurooncol, 2009, 91:329-336. doi:  10.1007/s11060-008-9718-y
    [40] Franceschi E, Cavallo G, Scopece L, et al. Phase Ⅱ trial of carboplatin and etoposide for patients with recurrent highgrade glioma[J]. Br J Cancer, 2004, 91:1038-1044. doi:  10.1038/sj.bjc.6602105
    [41] Sheleg SV, Korotkevich EA, Zhavrid EA, et al. Local chemotherapy with cisplatin-depot for glioblastoma multiforme[J]. J Neurooncol, 2002, 60:53-59. doi:  10.1023/A:1020288015457
    [42] Verhaak RGW, Hoadley KA, Purdom E. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1[J]. Cancer Cell, 2010, 17:98-101. doi:  10.1016/j.ccr.2009.12.020
    [43] Van MEG, Hadjipanayis CG, Norden AD. Exciting new advances in neuro-oncology:the avenue to a cure for malignant glioma[J]. CA Cancer J Clin, 2010, 60:166-193. doi:  10.3322/caac.20069
    [44] Schor NF. Pharmacotherapy for adults with tumors of the central nervous system[J]. Pharmacol Ther, 2009, 121:253-264. doi:  10.1016/j.pharmthera.2008.11.003
    [45] Tews DS, Nissen A, Kulgen C, et al. Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors[J]. J Neurooncol, 2000, 50:227-237. doi:  10.1023/A:1006491405010
    [46] Haga S, Hinoshita E, Ikezaki K, et al. Involvement of the multidrug resistance protein 3 in drug sensitivity and its expression in human glioma[J]. Jpn J Cancer Res, 2001, 92:211-219. doi:  10.1111/j.1349-7006.2001.tb01084.x
    [47] Kappadakunnel M, Eskin A, Dong J, et al. Stem cell associated gene expression in glioblastoma multiforme:relationship to survival and the subventricular zone[J]. J Neurooncol, 2010, 96:359-367. doi:  10.1007/s11060-009-9983-4
    [48] Eramo A, Ricci-Vitiani L, Zeuner A, et al. Chemotherapy resistance of glioblastoma stem cells[J]. Cell Death Differ, 2006, 13:1238-1241. doi:  10.1038/sj.cdd.4401872
    [49] Hussain SF, Heimberger AB. Immunotherapy for human glioma:innovative approaches and recent results[J]. Expert Rev Anticancer Ther, 2005, 5:777-790. doi:  10.1586/14737140.5.5.777
  • 加载中
表(1)
计量
  • 文章访问数:  135
  • HTML全文浏览量:  42
  • PDF下载量:  5
  • 被引次数: 0
出版历程
  • 收稿日期:  2011-11-02
  • 刊出日期:  2012-07-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!